Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.
暂无分享,去创建一个
[1] Xinrong Ma,et al. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. , 2006, Cancer research.
[2] C. Divino,et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. , 2006, Cancer research.
[3] J. Leips,et al. Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression1 , 2006, The Journal of Immunology.
[4] S. Albelda,et al. Cycloxygenase-2 Inhibition Augments the Efficacy of a Cancer Vaccine , 2006, Clinical Cancer Research.
[5] L. Coussens,et al. The inflammatory tumor microenvironment and its impact on cancer development. , 2006, Contributions to microbiology.
[6] S. Segal,et al. CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1β-Secreting Cells1 , 2005, The Journal of Immunology.
[7] R. Cardiff,et al. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. , 2005, Cancer research.
[8] S. Dubinett,et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma , 2005, The Journal of experimental medicine.
[9] L. Kaiser,et al. Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity , 2005, Clinical Cancer Research.
[10] Li Zhu,et al. Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells1 , 2005, The Journal of Immunology.
[11] M. Huang,et al. Cyclooxygenase 2 Inhibition Promotes IFN-γ-Dependent Enhancement of Antitumor Responses1 , 2005, The Journal of Immunology.
[12] M. Huang,et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. , 2005, Cancer research.
[13] A. Mantovani,et al. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.
[14] P. Sinha,et al. Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease1 , 2005, The Journal of Immunology.
[15] B. Fingleton,et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.
[16] Michael T. Lotze,et al. Inflammation and necrosis promote tumour growth , 2004, Nature Reviews Immunology.
[17] P. Sinha,et al. Surgical Removal of Primary Tumor Reverses Tumor-Induced Immunosuppression Despite the Presence of Metastatic Disease , 2004, Cancer Research.
[18] Qingsheng Li,et al. Role of Immature Myeloid Gr-1+ Cells in the Development of Antitumor Immunity , 2004, Cancer Research.
[19] R. Jove,et al. Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer , 2004, The Journal of Immunology.
[20] S. Cingarlini,et al. Derangement of immune responses by myeloid suppressor cells , 2004, Cancer Immunology, Immunotherapy.
[21] J. Berzofsky,et al. Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance , 2003, The Journal of Experimental Medicine.
[22] G. Anderson,et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. , 2003, Cancer research.
[23] P. De Baetselier,et al. Nitric Oxide-Independent CTL Suppression during Tumor Progression: Association with Arginase-Producing (M2) Myeloid Cells1 , 2003, The Journal of Immunology.
[24] R. DuBois,et al. Evaluation of the whole prostaglandin biosynthetic pathway in lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] F. Ramsdell,et al. An essential role for Scurfin in CD4+CD25+ T regulatory cells , 2003, Nature Immunology.
[26] A. Rudensky,et al. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.
[27] J. Morrow,et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. , 2003, The Journal of clinical investigation.
[28] Y. Iwakura,et al. IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[29] Jilly F. Evans,et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. , 2003, Cancer research.
[30] T. Nomura,et al. Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .
[31] R. DuBois,et al. Cyclooxygenase-2 and colorectal cancer. , 2003, Progress in experimental tumor research.
[32] P. Allavena,et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.
[33] E. Voronov,et al. Interleukin-1--a major pleiotropic cytokine in tumor-host interactions. , 2002, Seminars in cancer biology.
[34] Kazuhiro Usui,et al. Proinflammatory Cytokine IL-1β Promotes Tumor Growth of Lewis Lung Carcinoma by Induction of Angiogenic Factors: In Vivo Analysis of Tumor-Stromal Interaction1 , 2002, The Journal of Immunology.
[35] D. Gabrilovich,et al. Immature myeloid cells and cancer-associated immune suppression , 2002, Cancer Immunology, Immunotherapy.
[36] A. Fulton,et al. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. , 2002, Cancer research.
[37] J. Isola,et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. , 2002, Cancer research.
[38] S. Weitzman,et al. Chronic inflammation and cancer. , 2002, Oncology.
[39] A. Visintin,et al. Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism1 , 2002, The Journal of Immunology.
[40] T. Sugimura,et al. Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. , 2001, Carcinogenesis.
[41] V. Bronte,et al. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. , 2001, Journal of immunotherapy.
[42] D. Gabrilovich,et al. Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells1 , 2001, The Journal of Immunology.
[43] R. Schreiber,et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.
[44] Alberto Mantovani,et al. Inflammation and cancer: back to Virchow? , 2001, The Lancet.
[45] Nicholas R. English,et al. Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.
[46] J. Masferrer,et al. COX‐2 is expressed in human pulmonary, colonic, and mammary tumors , 2000, Cancer.
[47] R. Ronca,et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. , 2000, Blood.
[48] H. Adami,et al. Infections as a major preventable cause of human cancer , 2000, Journal of internal medicine.
[49] Shu-Hsia Chen,et al. Gr-1+ Myeloid Cells Derived from Tumor-Bearing Mice Inhibit Primary T Cell Activation Induced Through CD3/CD28 Costimulation1 , 2000, The Journal of Immunology.
[50] K. Seibert,et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.
[51] E. Shohami,et al. Induction of antitumor immunity by indomethacin , 2000, Cancer Immunology, Immunotherapy.
[52] J. Shimizu,et al. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.
[53] T. Fujita,et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.
[54] P. Hwu,et al. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. , 1999, Journal of immunology.
[55] J. Shah,et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. , 1999, Cancer research.
[56] 鬼塚 正三郎. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody , 1999 .
[57] M. Taketo. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). , 1998, Journal of the National Cancer Institute.
[58] S. Ostrand-Rosenberg,et al. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. , 1998, Cancer research.
[59] J. Morrow,et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. , 1998, Cancer research.
[60] M. Taketo. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). , 1998, Journal of the National Cancer Institute.
[61] F. Calvo,et al. Interleukin 1-dependent and -independent mouse melanoma metastases. , 1997, Journal of the National Cancer Institute.
[62] H. Mcdevitt,et al. CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. , 1996, Journal of immunology.
[63] A. Heimberger,et al. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. , 1990, Science.
[64] I. M. Neiman,et al. [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.